Pesquisar
MoonLake Immunotherapeutics
MLTXAdicionar à lista de desejos
19.110USD
-0.021-0.11%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.36BValor de mercado
PerdaP/L TTM
Mais detalhes de MoonLake Immunotherapeutics Empresa
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Informações de MoonLake Immunotherapeutics
Código da empresaMLTX
Nome da EmpresaMoonLake Immunotherapeutics
Data de listagemOct 20, 2020
CEOSantos Da Silva (Jorge)
Número de funcionários100
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 20
EndereçoDorfstrasse 29
CidadeZUG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postal6300
Telefone41415108022
Sitehttps://moonlaketx.com/
Código da empresaMLTX
Data de listagemOct 20, 2020
CEOSantos Da Silva (Jorge)
Executivos da empresa MoonLake Immunotherapeutics
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de MoonLake Immunotherapeutics?
Os cinco principais acionistas de MoonLake Immunotherapeutics são: Dr. Kristian Reich
Quantas instituições possuem ações da MoonLake Immunotherapeutics (MLTX)?
Em 2026Q1, 358 instituições possuíam ações da MoonLake Immunotherapeutics, com valor de mercado aproximado de 54.44M, representando 74.73% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3151979.00.